In 54 children with newly diagnosed severe aplastic anaemia, adding hetrombopag to immunosuppressive therapy did not improve the 6-month complete response rate (59.3% vs 62.9%, P=0.948); eight grade ≥3 adverse events occurred with hetrombopag.
RCTn = 54
Fu et al. First-line hetrombopag combined with immunosuppressive therapy for paediatric severe aplastic anaemia: A prospective randomized controlled trial